Melanoma "immune + targeted" treatment! The three drug regimen of Roche tecentriq was successful in the treatment of stage III of BRAF V600 positive advanced patients!

December 14, 2019 / BIOON / -- Roche recently announced the positive results of the phase III study of the melanoma The study, a double-blind, placebo-controlled study, was conducted in patients with previously untreated BRAF V600 mutation positive advanced melanoma to evaluate the efficacy and safety of PD-L1 tumor immunotherapy tecentriq (atezolizumab) combined with targeted anticancer drugs cotellic (cobimetinib) and zelboraf (vemurafenib) The results showed that the study reached the primary end point of progression free survival (PFS): compared with the placebo + cotellic + zelboraf group, the tecentriq + cotellic + zelboraf group showed significant and clinically significant improvement in PFS The safety profiles observed in this study are consistent with those known for each drug The detailed results of the study will be presented at an upcoming medical conference and will be discussed with regulators including the U.S Food and Drug Administration (FDA) and the European Drug Administration (EMA) Levi Garraway, MD, chief medical officer and head of global product development at Roche, said: "by combining cancer immunotherapy with targeted therapy, we hope to provide a new way to improve the prognosis of patients with BRAF mutant advanced melanoma We look forward to discussing the results with regulators around the world " Tecentriq (atezolizumab) is a tumor immunotherapy Its active drug ingredient is atezolizumab, which is a monoclonal antibody targeting PD-L1 protein It aims to bind PD-L1 on the surface of tumor cells and tumor infiltrating immune cells, and block its binding with PD-1 and B7.1 receptors Tecentriq can reactivate T cells by inhibiting PD-L1 Cotellic is an oral small molecule MEK1 / 2 inhibitor, which was discovered by exelixis company and jointly developed by Roche and exelixis Zelboraf is a powerful BRAF inhibitor, which can inhibit some mutated types of BRAF It is the first approved drug in this kind of drug It was jointly developed according to the license and cooperation agreement of Roche and plexxikon in 2006 MEK and BRAF are key protein kinases in the MAPK signaling pathway (RAS-RAF-MEK-ERK) It has been shown that this pathway regulates many key cell activities including cell proliferation, differentiation, survival and angiogenesis In many cancers, such as melanoma, colorectal cancer, and thyroid cancer, proteins in this signaling pathway have been shown to be abnormally activated At present, the combination therapy of cotellic + zelboraf has been approved in many countries around the world for the treatment of melanoma patients whose tumors have spread to other parts of the body or cannot be surgically removed and carry BRAF V600 mutation Roche has developed a wide range of clinical trial development plans for tecentriq, and is currently conducting more than 50 studies, including multiple phase III studies on lung cancer, kidney cancer, skin cancer, breast cancer, colorectal cancer, prostate cancer, ovarian cancer, bladder cancer, blood cancer, liver cancer and head and neck cancer These studies are evaluating tecentriq as a monotherapy and in combination with other drugs Source of the original text: Roche announces positive phase III study results for tecentriq plus cottellic and zelboraf in people with previously untreated BRAF V600 vibration position advanced Mexico